ViroGates A/S (VIRO) - Total Assets
Based on the latest financial reports, ViroGates A/S (VIRO) holds total assets worth Dkr14.21 Million DKK (≈ $2.22 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ViroGates A/S (VIRO) net assets for net asset value and shareholders' equity analysis.
ViroGates A/S - Total Assets Trend (2015–2024)
This chart illustrates how ViroGates A/S's total assets have evolved over time, based on quarterly financial data.
ViroGates A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
ViroGates A/S's total assets of Dkr14.21 Million consist of 99.0% current assets and 1.0% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 69.1% |
| Accounts Receivable | Dkr1.62 Million | 9.2% |
| Inventory | Dkr2.81 Million | 15.9% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr0.00 | 0.0% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how ViroGates A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ViroGates A/S stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ViroGates A/S's current assets represent 99.0% of total assets in 2024, an increase from 97.5% in 2015.
- Cash Position: Cash and equivalents constituted 69.1% of total assets in 2024, down from 83.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 15.9% of total assets.
ViroGates A/S Competitors by Total Assets
Key competitors of ViroGates A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $1.36 Billion |
|
Sino Medical Sciences Technology In
SHG:688108
|
China | CN¥1.34 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥965.27 Million |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
ViroGates A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 8.30 | 5.43 |
| Quick Ratio | 1.58 | 6.13 | 5.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr6.29 Million | Dkr12.21 Million | Dkr30.71 Million |
ViroGates A/S - Advanced Valuation Insights
This section examines the relationship between ViroGates A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 39.12 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | -28.1% |
| Total Assets | Dkr17.66 Million |
| Market Capitalization | $15.97 Million USD |
Valuation Analysis
Near Book Valuation: The market values ViroGates A/S's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: ViroGates A/S's assets decreased by 28.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ViroGates A/S (2015–2024)
The table below shows the annual total assets of ViroGates A/S from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr17.66 Million ≈ $2.76 Million |
-28.08% |
| 2023-12-31 | Dkr24.55 Million ≈ $3.84 Million |
+40.00% |
| 2022-12-31 | Dkr17.54 Million ≈ $2.74 Million |
-13.30% |
| 2021-12-31 | Dkr20.23 Million ≈ $3.16 Million |
-47.11% |
| 2020-12-31 | Dkr38.25 Million ≈ $5.98 Million |
-15.30% |
| 2019-12-31 | Dkr45.16 Million ≈ $7.07 Million |
-28.80% |
| 2018-12-31 | Dkr63.42 Million ≈ $9.92 Million |
+1174.07% |
| 2017-12-31 | Dkr4.98 Million ≈ $778.84K |
-58.51% |
| 2016-12-31 | Dkr12.00 Million ≈ $1.88 Million |
-31.11% |
| 2015-12-31 | Dkr17.41 Million ≈ $2.72 Million |
-- |
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic he… Read more